Vlad Coric, Biohaven CEO
Over a year after FDA rejection, Biohaven claims success in pivotal muscle disease study
Biohaven is seeking to reverse the fate of its embattled experimental drug troriluzole in spinocerebellar ataxia — a degenerative muscle disease — using new clinical trial results …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.